ProSomnus announces publication of study on its precision OAT devices

ProSomnus announced the publication of a study by the Cureus Journal of Medical Science, in which the Company’s precision oral appliance therapy, OAT, devices successfully treated patients’ OSA. Key findings from the study, titled “Evaluating the Clinical Performance of a Novel, Precision Oral Appliance Therapy Medical Device Made Wholly from a Medical Grade Class VI Material for the Treatment of Obstructive Sleep Apnea,” include: 89% of all patients and 98.5% of mild to moderate OSA patients were treated to an apnea-hypopnea index of fewer than 10 events per hour. 80% of severe OSA patients were treated to an AHI of fewer than 20 events per hour with a 50% improvement. After a minimum one-year follow-up period, 96% of patients continued using their precision OAT devices. ProSomnus also announced additional clinical research highlighting the efficacy, decreased AHI incidents, and strong therapy adherence associated with the Company’s precision OAT devices: In a six-center study assessing the efficacy, repeatability and predictability of treating 58 moderate to severe OSA patients with ProSomnus(R) EVO(R) and a standard treatment protocol, participants’ median obstructive AHI decreased from 20.54 to 3.9 events per hour, while 90% of patients experienced fewer than 15 events per hour. In a study of 22 mild to moderate OSA patients, the ProSomnus EVO was associated with a decreased AHI and strong compliance. After being treated with the EVO, patients’ median AHI decreased from 21 to 4 events per hour, while 95% of patients experienced fewer than 10 events per hour. Patients’ compliance with the EVO, reported in the first three months of therapy, was 100%.